LLY · ELI LILLY & Co
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Research
our published analysis of this company
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| acquired in-process research and development (IPR&D) charges | $584M | Q1 2026 | — |
| Key Products revenue | $13.4B | Q1 2026 | — |
| Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas | 160% | Q1 2026 | — |
| one-time benefits | $250M | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LLY
this stock
ELI LILLY & Co
|
$1.18T | +16.8% | +44.7% | 42.1 | 1.0% |
|
JNJ
Johnson & Johnson
|
$651.25B | +30.6% | +6.0% | 31.4 | 1.1% |
|
ABBV
AbbVie Inc.
|
$468.22B | +16.0% | +8.6% | 74.9 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$376.37B | +44.9% | +1.3% | 122.0 | 1.1% |
|
NVS
Novartis AG
|
$301.95B | +15.2% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LLY | +6.4% | +5.0% | +23.3% | +9.3% | +16.8% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +7.8% | +1.3% | +11.8% | +6.8% | +4.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.